EGFR and non-small cell lung carcinoma: Additionally, in EGFR mutant NSCLC activation of the WNT/β-catenin pathway may limit EGFR inhibitor response and may promote survival of a persister cell population during EGFR inhibitor therapy in vitro (Arasada et al., 2018; Blakely et al., 2017; Casás-Selves et al., 2012; Nakayama et al., 2014).